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Abstract
Background: To evaluate the impact of infusion set use duration on glycemic control, we conducted an
Internet-based study using the T1D Exchange’s online patient community, Glu (myGlu.org).
Subjects and Methods: For 14 days, 243 electronically consented adults with type 1 diabetes (T1D) entered
online that day’s fasting blood glucose (FBG) level, the prior day’s total daily insulin (TDI) dose, and whether
the infusion set was changed.
Results: Mean duration of infusion set use was 3.0 days. Mean FBG level was higher with each successive day
of infusion set use, increasing from 126 mg/dL on Day 1 to 133 mg/dL on Day 3 to 147 mg/dL on Day 5
(P< 0.001). TDI dose did not vary with increased duration of infusion set use.
Conclusions: Internet-based data collection was used to rapidly conduct the study at low cost. The results
indicate that FBG levels increase with each additional day of insulin pump infusion set use.
Introduction
Few studies have evaluated the impact of duration ofinsulin pump infusion set use on glycemic control or
outlined guidelines for when an infusion set should be
changed.1–6 A white paper published from the proceedings
of an American Association of Diabetes Educators consensus
panel noted the lack of literature regarding subcutaneous
insulin infusion devices.7 To address this gap in evidence,
we conducted an Internet-based study using the T1D
Exchange’s online patient community, Glu (myGlu.org). The
study also provided the opportunity to assess the feasibility of
using online data collection for longitudinal studies.
Subjects and Methods
Participants were recruited from the T1D Exchange’s online
patient community, Glu. E-mails were sent to Glu members
who indicated a preference to be contacted about research
studies. Additionally, information about the study was provided
on Glu, Facebook, and Twitter. Eligibility criteria included age
‡18 years, diagnosis of type 1 diabetes (T1D), and daily use of
an insulin pump. Participants signed an institutional review
board–approved electronic informed consent form. Participants
received no compensation for taking part in the study.
Participants completed a questionnaire on their diabetes
history, diabetes management, pump use, and most recent
hemoglobin A1c (HbA1c) level. For 14 days, participants
received daily e-mail prompts to report the following infor-
mation using a computer or other device: that day’s fasting
blood glucose (FBG) level, the prior day’s total daily insulin
(TDI) dose, and whether the infusion set was changed.
To be included in the analyses, a participant must have com-
pleted data entry at least 3 of the 14 days. When infusion set use
was more than 5 days, only the first 5 days were analyzed owing
to the small number of infusion sets used for more than 5 days.
Statistical methods
Linear regression models were used to examine the asso-
ciation between (1) typical duration of infusion set wear and
1Jaeb Center for Health Research, Tampa, Florida.
2Unitio, Boston, Massachusetts.
3University of Michigan, Ann Arbor, Michigan
4Stanford University, Stanford, California.
DIABETES TECHNOLOGY & THERAPEUTICS
Volume 17, Number 5, 2015
ª Mary Ann Liebert, Inc.
DOI: 10.1089/dia.2014.0336
307
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f M
ic
hi
ga
n 
e-
jou
rna
l p
ack
ag
e f
rom
 on
lin
e.l
ieb
ert
pu
b.c
om
 at
 12
/08
/17
. F
or 
pe
rso
na
l u
se 
on
ly.
 
annual household income and (2) self-reported HbA1c and
typical duration of infusion set wear. Linear mixed models
with repeated measures were used to separately examine the
association between FBG and TDI dose, with day of infusion
set use accounting for the correlation due to multiple measures
per participant. To account for possible confounding due to the
potential for participants with higher FBG levels to wear in-
fusion sets longer, average duration of infusion set wear was
included as an adjustment covariate in the model. The analyses
were repeated in the participant subset that completed all 14
daily questionnaires, with results similar to those from the
main analysis (data not shown).
Data analyses used SAS software, version 9.3 (2011; SAS
Institute Inc., Cary, NC). All P values are two-sided.
Results
Of the 317 participants who completed the electronic
consent process, 14 (4%) did not complete the enrollment
questionnaire, 45 (14%) failed to enter any daily study data,
and 15 (5%) completed <3 days of data collection. A cohort of
243 participants was included in the study analyses. Among
the 243 participants, 173 (71%) enrolled on the day the study
was announced, 29 (12%) on the second day, eight (3%) on
the third day, and the remaining 33 (14%) within 11 days.
Mean age of the 243 participants was 42 – 14 years (13%,
18–25 years; 36%, 26–40 years; 41%, 41–60 years; and 11%,
‡61 years), median duration of diabetes was 22 years (in-
terquartile range, 12–35 years), 91% were non-Hispanic
white, 73% were female, and 29% had an annual household
income of ‡ $100,000 (10%, <$35,000; 25%, $35,000–
<$75,000; and 19%, $75,000– <$100,000; 16% did not pro-
vide annual income information). Among study participants,
63% reported using a continuous glucose monitor. Mean
HbA1c level was 6.9 – 1.1%. Typical duration of infusion set
use was not related to income; mean typical duration of in-
fusion set use was 3.7, 3.3, 3.5, and 3.5 days for annual in-
come of <$35,000, $35,000– <$75,000, $75,000– <$100,000,
and ‡$100,000, respectively (P = 0.58). Mean HbA1c level
was 7.0% for participants typically changing the infusion set
every 2–3 days and 6.7% for those who changed every 4 or
more days (P = 0.03).
The types of insulin pumps used by the participants are
shown in Table 1. Insulin pump use was at least 3 years
Table 1. Insulin Pump Use Prior to Study
Value
Total number of subjects 243
Duration of insulin pump use on a daily basis
<6 months 12 (5%)
6 months–<1 year 10 (4%)
1 year–<2 years 16 (7%)
2 years–<3 years 18 (7%)
‡ 3 years 187 (77%)
Duration of use of current pump
<6 months 38 (16%)
6 months–<1 year 43 (18%)
1 year–<2 years 62 (26%)
2 years–<3 years 41 (17%)
‡3 years 59 (24%)
Brand of insulin pump
Animas 64 (26%)
Insulet 17 (7%)
Medtronic 147 (60%)
Roche 3 (1%)
Smith’s Medical 4 (2%)
Tandem 7 (3%)
Unknown 1 (<1%)
Type of infusion set
30 Teflon 11 (5%)
90 Teflon 127 (52%)
90 steel 9 (4%)
Unknown 96 (40%)
Typical frequency of infusion set change
Every other day 12 (5%)
Every 3 days 160 (66%)
Every 4 days 45 (19%)
Every 5 days 12 (5%)
Every 6 days 8 (3%)
Every 7 days 3 (1%)
More than 7 days 3 (1%)
Frequency of earlier than usual infusion set change due
to concern about insulin delivery in the last 3 months
None 35 (14%)
1 time 51 (21%)
2 times 63 (26%)
3 times 38 (16%)
4 times 23 (9%)
‡5 times 33 (15%)
Data are number (%).
Table 2. Glycemic Control and Insulin Amount According to Day of Infusion Set Use
Day 1 Day 2 Day 3 Day 4 Day 5
Fasting blood glucose (mg/dL)
n 236 236 230 163 77
Mean – SD 125 – 39 128– 44 133– 49 140 – 56 147– 68
Median (interquartile range) 119 (100, 146) 116 (99, 149) 125 (97, 158) 132 (94, 171) 128 (99, 174)
%> 180 mg/dL 9% 13% 15% 21% 22%
%> 250 mg/dL 1% 1% 3% 4% 8%
Total daily insulin (units)
n 236 230 163 77 40
Mean – SD 40.1 – 20.5 39.6 – 19.5 37.9 – 16.6 36.7 – 16.4 39.3 – 15.8
Median (interquartile range) 35.6 (27.0, 45.4) 34.9 (27.0, 45.5) 34.5 (28.0, 45.5) 35.0 (27.0, 43.0) 37.5 (29.5, 46.5)
When infusion set use was more than 5 days, only the first 5 days were analyzed because of the small number of infusion sets used more
than 5 days.
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Table 3. Fasting Blood Glucose by Day of Infusion Set Wear
for Subsets of Duration of Infusion Set Wear
Fasting blood glucose level (mg/dL)
Days of infusion set wear Day 1 Day 2 Day 3 Day 4 Day 5
3 (n = 67)
Mean – SD 125 – 33 133– 44 142 – 53 — —
Median (interquartile range) 122 (104, 145) 121 (104, 152) 131 (101, 172) — —
4 (n = 86)
Mean – SD 127 – 42 127– 42 132 – 44 148– 60 —
Median (interquartile range) 116 (100, 142) 115 (100, 148) 123 (95, 161) 142 (99, 180) —
5 (n = 75)
Mean – SD 125 – 41 125– 47 125 – 49 131– 54 147– 68
Median (interquartile range) 120 (92, 151) 113 (91, 149) 118 (91, 142) 122 (90, 155) 128 (98, 174)
When infusion set use was more than 5 days, only the first 5 days were analyzed because of the small number of infusion sets used more
than 5 days.
Table 4. Glycemic Control by Demographic and Clinical Factors According to Day of Infusion Set Use
Fasting blood glucose (mg/dL)
Day 1 Day 2 Day 3 Day 4 Day 5 P value
Factor n Mean – SD n Mean – SD n Mean – SD n Mean – SD n Mean – SD Unadjusteda Adjustedb
Gender 0.30 0.64
Female 173 127 – 39 173 129 – 45 170 135 – 52 122 138 – 56 65 148 – 69
Male 63 122 – 39 63 124 – 43 60 128 – 41 41 146 – 63 12 141 – 61
Age (years) 0.07 0.63
18–25 30 146 – 40 30 139 – 50 29 136 – 51 21 140 – 52 11 133 – 44
26–40 83 123 – 37 83 128 – 43 81 138 – 52 62 144 – 59 36 138 – 58
41–60 97 124 – 40 97 123 – 44 95 130 – 49 66 136 – 61 28 168 – 84
‡ 61 26 114 – 37 26 131 – 41 25 128 – 35 14 137 – 52 2 105 – 30
Race/ethnicity 0.33 0.50
White non-Hispanic 216 126 – 40 216 127 – 45 212 133 – 49 150 139 – 57 68 151 – 69
Black non-Hispanic 1 92 1 130 1 70 1 138 1 65
Hispanic or Latino 8 102 – 29 8 121 – 29 7 116 – 36 5 178 – 101 3 130 – 77
Other race/ethnicity 11 131 – 35 11 145 – 43 10 150– 57 7 124 – 33 5 126 – 45
Type 1 diabetes
duration (years)
0.03 0.22
£9 46 131 – 48 46 125 – 43 45 130 – 47 37 130 – 54 17 129 – 39
10– £20 57 137 – 37 57 141 – 48 55 139 – 52 36 160 – 74 15 125 – 64
21– £31 63 129 – 38 63 127 – 45 62 143 – 55 46 149 – 46 26 148 – 53
>31 70 110 – 31 70 119 – 40 68 122 – 39 44 122 – 51 19 181 – 96
Annual income 0.74 0.65
<$35,000 22 136 – 52 22 145 – 50 22 129 – 57 16 145 – 87 10 147 – 63
$35,000–<$75,000 63 125 – 36 63 123 – 40 62 125 – 45 43 132 – 45 17 154 – 77
$75,000–<$100,000 45 121 – 37 45 125 – 48 44 137 – 50 32 141 – 53 18 154 – 70
‡$100,000 68 124– 34 68 126 – 43 66 133 – 46 43 144 – 48 17 139 – 59
Not provided 38 128 – 48 38 132 – 45 36 145 – 54 29 141 – 74 15 141 – 75
Brand of insulin pump 0.43 0.88
Animas 62 133 – 42 62 130 – 39 61 132 – 47 44 138 – 56 20 139 – 52
Insulet 17 121 – 34 17 118 – 37 16 125 – 52 5 139 – 54 0 —
Medtronic 143 124 – 39 143 129 – 48 139 135 – 50 102 139 – 59 53 154 – 74
Roche 2 126 – 17 2 111 – 51 2 127 – 47 2 212 – 28 1 123
Smith’s Medical 4 96 – 15 4 106 – 23 4 98 – 30 4 126 – 34 2 96 – 43
Tandem 7 126 – 26 7 121 – 50 7 151 – 58 5 159 – 66 0 —
Type of insulinc 0.87 0.71
Apidra (insulin glulisine) 22 122 – 35 22 128 – 50 20 158 – 73 11 143 – 55 2 153 – 91
Humalog (insulin lispro) 109 126 – 38 109 133 – 44 108 136 – 48 76 139 – 50 33 152 – 65
Novolog (insulin aspart) 104 126 – 42 104 123 – 43 101 125 – 43 75 141 – 66 41 145 – 71
aUnadjusted P values from a linear mixed model with repeated measures adjusted for average duration of infusion set wear. Only the
adjustment factor, day of infusion set wear, and the indicated factor were included in the model. Age and duration of type 1 diabetes were
included as continuous factors.
bAdjusted P values from a linear mixed model with repeated measures adjusted for average duration of infusion set wear. In addition to
the adjustment factor and day of infusion set wear, all factors in the table were included in model. Age and duration of type 1 diabetes were
included as continuous factors.
cOne participant reported using Humalog R U-500.
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in 77% of participants, with 66% of participants usually
changing their infusion set every 3 days.
Outcome data
Daily data were entered for all 14 days by 213 (71%) of the
243 participants, 10–13 days by eight (3%), 6–9 days by 12
(5%), and 3–5 days by 10 (4%). During the study, the 243
participants reported using a total of 688 infusion sets. Mean
duration of infusion set use during the study was 3.0 – 1.0
days: 1–2 days for 26%, 3 days for 48%, 4 days for 19%, and
5 days for 7%.
Mean FBG increased with each additional day of infusion
set wear, increasing from 125 mg/dL on Day 1 to 133 mg/dL
on Day 3 to 147 mg/dL on Day 5 (P < 0.001) (Table 2). It is
interesting that for infusion sets used for 4 days, there was not
a substantial increase in the mean FBG until Day 4, and for
infusion sets used for 5 days, there was not a substantial
increase until Day 5 (Table 3). Other than duration of infusion
set use, no other factors were associated with the increase in
mean glucose level as seen from Day 1 to Day 5 (Table 4).
Mean TDI dose remained relatively constant from Day 1 to
Day 5 (from 40 to 39 units/day) (P = 0.94).
Discussion
Our study used online data collection to address an important
clinical question much more rapidly and at lower cost than
comparable clinic-based studies. Within 2 days of announcing
the study, more than 200 participants had enrolled, and the
study was essentially completed within 1 month of initiation.
Participants were not compensated, so costs for the study were
limited to programming for the Web site’s data collection
capabilities and data analyses. The study’s main finding was
that FBG levels increased with each day of infusion set use. It is
particularly noteworthy that for those infusion sets used for 4
and 5 days, mean FBG only modestly increased until Day 4 and
5, respectively. Thus patients seem to be able to autotitrate the
frequency in which they need to change their infusion sites.
Our findings are consistent with a small prior study con-
ducted in 20 adults with T1D that found that from Day 2 to
Day 5 of infusion set use, FBG increased from 120 to 155 mg/
dL.8 In that study, TDI dose increased from 48.5 – 11.8 units
to 55.3 – 17.9 units, whereas we did not find an increase in
TDI dose in our subjects.
In assessing the feasibility of conducting a study using
online data collection, potential biases that may be present
depending on the characteristics of the participants and the
lack of direct monitoring by clinic personnel may require
further evaluation. In the case of the current study, even
though our participants were better controlled than most
adults with T1D in the United States and more likely to be
using continuous glucose monitoring,9 bias with respect to
the study participants seems unlikely to have had a major
effect on the results because no other factors were found to be
associated with the increase in FBG over time. Additionally,
because data were entered daily by participants, it seems
unlikely that study participants would have falsely entered
FBG values. Although FBG data were not verified, a study
such as this could have done so if it was required through the
uploading of blood glucose meter data at the end of the study.
In conclusion, this study demonstrates the power of using
online data collection and a T1D social network to conduct
longitudinal clinical research studies rapidly at low cost. The
results of the study indicate that FBG levels increase each day of
successive insulin pump infusion set use, which is important for
insulin pump users and their healthcare providers to recognize.
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